CareDx Inc (CDNA)vsNatera Inc (NTRA)
CDNA
CareDx Inc
$28.82
-3.76%
HEALTHCARE · Cap: $1.20B
NTRA
Natera Inc
$261.91
-3.06%
HEALTHCARE · Cap: $38.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 506% more annual revenue ($2.50B vs $412.82M). CDNA leads profitability with a -2.0% profit margin vs -9.1%. CDNA earns a higher WallStSmart Score of 37/100 (F).
CDNA
Hold37
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$46.59
Current Price
$28.82
$17.77 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.0% year-over-year
Conservative balance sheet, low leverage
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 1.5%
Weak financial health signals
0.0% earnings growth
Weak financial health signals
Trading at 21.1x book value
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity. Revenue growth of 39.0% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are EPS Growth, Market Cap, Operating Margin.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
CDNA carries more volatility with a beta of 2.48 — expect wider price swings.
CDNA is growing revenue faster at 39.0% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CDNA scores higher overall (37/100 vs 31/100) and 39.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?